Keros Therapeutics (KROS) Cash & Equivalents (2019 - 2025)

Keros Therapeutics (KROS) has 7 years of Cash & Equivalents data on file, last reported at $287.4 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents fell 48.67% year-over-year to $287.4 million; the trailing twelve-month figure through Dec 2025 stood at $287.4 million (down 48.67% YoY), and the FY2025 full-year result was $287.4 million, down 48.67% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $287.4 million, down from $693.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $720.5 million in Q1 2025 and bottomed at $215.6 million in Q2 2022.
• The 5-year median for Cash & Equivalents is $305.0 million (2023), against an average of $376.5 million.
• The widest annual swing landed in 2021, when Cash & Equivalents jumped 368.11%; it then tumbled 48.67% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $230.0 million in 2021, then rose by 21.3% to $279.0 million in 2022, then grew by 18.67% to $331.1 million in 2023, then jumped by 69.09% to $559.9 million in 2024, then sank by 48.67% to $287.4 million in 2025.
• The last three Cash & Equivalents figures came in at $287.4 million (Q4 2025), $693.5 million (Q3 2025), and $690.2 million (Q2 2025), per Business Quant data.

Peer Comparison